ImmuPharma trades well below 6p placing price as P140 licensing remains the focus
ImmuPharma plc heads into the week still facing a gap in its share price. Shares climbed Friday, but the AIM-listed biotech closed way under the price of its April funding round. London was closed Sunday. The exchange runs Monday to Friday, 8 a.m. to 4:30 p.m., so Friday’s close is the latest price. The stock ended July 3 at 3.48p. That's up 150.7% from the 52-week low of 1.39p, but still down 82.1% from the 52-week high of 19.40p. Market cap stood at £21.68 million with 623.91 million shares out, per LSEG data on Investors Chronicle.